ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Calliditas Therapeutics AB

Calliditas Therapeutics AB (CALT)

39.14
-0.30
( -0.76% )
Updated: 13:14:26

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
39.14
Bid
38.65
Ask
39.55
Volume
7,000
38.65 Day's Range 39.26
0.00 52 Week Range 0.00
Market Cap
Previous Close
39.44
Open
39.15
Last Trade
1
@
38.76
Last Trade Time
13:34:58
Financial Volume
$ 273,581
VWAP
39.083
Average Volume (3m)
-
Shares Outstanding
26,836,035
Dividend Yield
-
PE Ratio
-0.43
Earnings Per Share (EPS)
-17.37
Revenue
1.21B
Net Profit
-466.19M

About Calliditas Therapeutics AB

Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients ... Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Stockholm, Swe
Founded
1970
Calliditas Therapeutics AB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CALT. The last closing price for Calliditas Therapeutics AB was $39.44. Over the last year, Calliditas Therapeutics AB shares have traded in a share price range of $ 0.00 to $ 0.00.

Calliditas Therapeutics AB currently has 26,836,035 shares outstanding. The market capitalization of Calliditas Therapeutics AB is $202.61 million. Calliditas Therapeutics AB has a price to earnings ratio (PE ratio) of -0.43.

CALT Latest News

Calliditas provides setanaxib patent update

Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...

Calliditas provides setanaxib patent update

Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, June 17, 2024 STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed...

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM, May 30, 2024...

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire STOCKHOLM, May 30, 2024 STOCKHOLM, May 30, 2024...

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire STOCKHOLM, May 28, 2024 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire STOCKHOLM, May 28, 2024 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RGSRegis Corporation
$ 18.05
(256.02%)
36.29M
VLCNVolcon Inc
$ 9.62
(147.94%)
23.39M
CPOPPop Culture Group Company Ltd
$ 1.9747
(71.71%)
29.96M
NNENano Nuclear Energy Inc
$ 31.5555
(51.20%)
10.36M
GRDIGRIID Infrastructure Inc
$ 2.0189
(46.30%)
7.96M
XAIRBeyond Air Inc
$ 0.7055
(-47.35%)
7.52M
ALLRAllarity Therapeutics Inc
$ 0.2215
(-30.56%)
25.71M
CRKNCrown Electrokinetics Corporation
$ 4.12
(-28.29%)
905.28k
LRELead Real Estate Company Ltd
$ 2.2598
(-26.63%)
1.1M
UNCYUnicycive Therapeutics Inc
$ 0.5101
(-25.28%)
4.91M
NVDANVIDIA Corporation
$ 124.12
(5.09%)
281.79M
FFIEFaraday Future Intelligent Electric Inc
$ 0.272611
(-16.38%)
127.63M
GLYCGlycoMimetics Inc
$ 0.3308
(24.08%)
114.58M
SQQQProShares UltraPro Short QQQ
$ 8.51
(-2.07%)
82.99M
LRHCLa Rosa Holdings Corporation
$ 1.9599
(30.66%)
66.26M

CALT Discussion

View Posts
tw0122 tw0122 4 weeks ago
$CALT $38 STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.

The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9 months was associated with estimated glomerular filtration rate (eGFR) benefit compared with continuous treatment with sparsentan.

Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids (SGC), such as Prednisone and Prednisolone.

"It was wonderful to participate in ERA 2024 and present data contributing to the discussion on the need for effective treatments in IgAN," said Richard Philipson, Chief Medical Officer of Calliditas, " We continue to gather evidence that highlights the importance of treating the underlying autoimmune pathogenesis associated with IgAN, and we believe TARPEYO, as the only approved immunomodulating therapy designed to target the production of Gd-IgA1, has the potential to become a cornerstone therapy in IgAN."

Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting.

Presentation Analyses:

Title: "Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan"

A matching-adjusted indirect comparison (MAIC) methodology is a widely accepted and relevant methodology for comparing treatments across trials in the absence of head-to-head comparisons. Here the effects of Nefecon, marketed as TARPEYO® and sparsentan, marketed as FILSPARI™, on kidney function deterioration in patients with IgAN were compared, as assessed by eGFR change from baseline at 9, 12 and 24 months. Results from the MAIC showed significantly favorable effects of Nefecon versus sparsentan on eGFR across all time points analyzed. Mean differences in the absolute change in eGFR of 5.68mL/min/1.73 m2 (95% credible interval [Crl] 3.14, 8.20; p
👍️0
Monksdream Monksdream 3 months ago
CALT over $20
👍️0

Your Recent History

Delayed Upgrade Clock